Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2105
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA ; volume:20 ; number:2 ; day:14 ; month:3 ; year:2019 ; pages:129-139 ; date:3.2019
BMC bioinformatics ; 20, Heft 2 (14.3.2019), 129-139, 3.2019
- Urheber
-
Wu, Leihong
Ingle, Taylor
Liu, Zhichao
Zhao-Wong, Anna
Harris, Stephen
Thakkar, Shraddha
Zhou, Guangxu
Yang, Junshuang
Xu, Joshua
Mehta, Darshan
Ge, Weigong
Tong, Weida
Fang, Hong
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12859-019-2628-5
- URN
-
urn:nbn:de:101:1-2019040716561153933799
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wu, Leihong
- Ingle, Taylor
- Liu, Zhichao
- Zhao-Wong, Anna
- Harris, Stephen
- Thakkar, Shraddha
- Zhou, Guangxu
- Yang, Junshuang
- Xu, Joshua
- Mehta, Darshan
- Ge, Weigong
- Tong, Weida
- Fang, Hong
- SpringerLink (Online service)
Ähnliche Objekte (12)
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
Synthesis and clinical application of new drugs approved by FDA in 2022
Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
Synthesis and clinical application of new drugs approved by FDA in 2022
Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
Synthesis and clinical application of new drugs approved by FDA in 2022